1. Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck.
- Author
-
Göksu SS, Tatlı AM, Geredeli Ç, Atcı M, Besen AA, Mertsoylu H, Uysal M, Özdoğan M, Aydın SG, Bilici A, Karaağaç M, Artaç M, Kaplan MA, Ebinç S, and Coşkun HŞ
- Subjects
- Adult, Aged, Aged, 80 and over, Cetuximab therapeutic use, Female, Head and Neck Neoplasms mortality, Head and Neck Neoplasms pathology, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Neutropenia chemically induced, Progression-Free Survival, Retrospective Studies, Squamous Cell Carcinoma of Head and Neck mortality, Squamous Cell Carcinoma of Head and Neck pathology, Treatment Outcome, Antineoplastic Agents, Immunological adverse effects, Cetuximab adverse effects, Exanthema chemically induced, Head and Neck Neoplasms drug therapy, Squamous Cell Carcinoma of Head and Neck drug therapy
- Abstract
Purpose: In this study, we looked for whether treatment-induced rash predicts treatment efficacy in patients with recurrent/metastatic HNSCC treated with Cetuximab and chemotherapy., Methods: Patients who were treated with platinum-based chemotherapy and cetuximab for the first line treatment of recurrent/metastatic HNSCC were recruited. Presence of rash, hypomagnesemia, hypopotassemia, anemia, neutropenia, thrombocytopenia during treatment and treatment response, date of progression, date of last visit and death were recorded., Results: A total of 138 patients' data were available for analysis. Any grade of rash was detected in 57 (44.5%) of the patients. The incidence of rash was significantly higher in patients with objective response than in patients with disease progression (%56.8 vs %14.3, p < 0.001). Progression free survival was 7.06 months (4.98-9.15) in patients treated with cetuximab and chemotherapy as first line treatment. In the multivariate analysis; rash was significantly correlated with longer PFS (HR 2.136; 95% CI 1.067-4.278; p = 0.032). Progression free survival was 9.65 months in patients who experienced rash, and 6.02 months in patients without rash, (p = 0.019, log-rank test). Overall survival was 11.24 months (9.65-12.82). In multivariate analysis, the survival of patients with rash was significantly longer than patients without rash (HR 1.954; 95% CI 1.162-3.285; p = 0.012). Overall survival was 15.08 months in patients who experienced rash, and 8.61 months in patients without rash (p = 0.05, log-rank test)., Conclusion: Cetuximab-induced rash is associated with better ORR and longer PFS and OS in patients with recurrent/metastatic HNSCC treated with Cetuximab and platinum-based chemotherapy., (© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2021
- Full Text
- View/download PDF